Monitoring genotoxicity in patients receiving chemotherapy for cancer: application of the PIG-A assay

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 808, Issue , 2016, Pages 20-26

  Horibata, Katsuyoshi ^a   Ukai, Akiko ^a   Ishikawa, Shigeo ^b   Sugano, Ayako ^b   Honma, Masamitsu ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Genotoxicity; Glycosylphosphatidylinositol anchor; Red blood cell

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDES AND PROTEINS; PIG A PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; ERYTHROCYTE; FEMALE; GENE MUTATION; GENOTOXICITY; HUMAN; MALE; PRIORITY JOURNAL; RETICULOCYTE; RETICULOCYTOSIS; AGED; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTAGEN TESTING; MUTATION RATE; NEOPLASMS; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ERYTHROCYTES; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTAGENICITY TESTS; MUTATION RATE; NEOPLASMS; RETICULOCYTES;

EID: 84983035681     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2016.08.002     Document Type: Article

References (33)

1. [1] Miura, D., Dobrovolsky, V.N., Mittelstaedt, R.A., Kasahara, Y., Katsuura, Y., Heflich, R.H., Development of an in vivo gene mutation assay using the endogenous Pig-A gene: II. Selection of Pig-A mutant rat spleen T-cells with proaerolysin and sequencing Pig-A cDNA from the mutants. Environ. Mol. Mutagen. 49 (2008), 622–630.
2. [2] Miura, D., Dobrovolsky, V.N., Kasahara, Y., Katsuura, Y., Heflich, R.H., Development of an in vivo gene mutation assay using the endogenous Pig-A gene: i. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat. Environ. Mol. Mutagen. 49 (2008), 614–621.
3. [3] Gollapudi, B.B., Lynch, A.M., Heflich, R.H., Dertinger, S.D., Dobrovolsky, V.N., Froetschl, R., Horibata, K., Kenyon, M.O., Kimoto, T., Lovell, D.P., Stankowski, L.F., White, P.A., Witt, K.L., Tanir, J.Y., The in vivo pig-a assay: a report of the international workshop on genotoxicity testing (IWGT) workgroup. Mutat. Res./Genet. Toxicol. Environ. Mutagen. 783 (2015), 23–35.
4. [4] Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., Kinoshita, T., Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993), 703–711.
5. [5] Araten, D.J., Nafa, K., Pakdeesuwan, K., Luzzatto, L., Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 5209–5214.
6. [6] Rondelli, T., Berardi, M., Peruzzi, B., Boni, L., Caporale, R., Dolara, P., Notaro, R., Luzzatto, L., The frequency of granulocytes with spontaneous somatic mutations: a wide distribution in a normal human population. PLoS One, 8, 2013, e54046.
7. [7] Miura, D., Dobrovolsky, V.N., Kimoto, T., Kasahara, Y., Heflich, R.H., Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosourea. Mutat. Res. 677 (2009), 86–92.
8. [8] Peruzzi, B., Araten, D.J., Notaro, R., Luzzatto, L., The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. Mutat. Res. 705 (2010), 3–10.
9. [9] Dobrovolsky, V.N., Elespuru, R.K., Bigger, C.A.H., Robison, T.W., Heflich, R.H., Monitoring humans for somatic mutation in the endogenous pig-a gene using red blood cells. Environ. Mol. Mutagen. 52 (2011), 784–794.
10. [10] Dertinger, S.D., Avlasevich, S.L., Bemis, J.C., Chen, Y., MacGregor, J.T., Human erythrocyte PIG-A assay: an easily monitored index of gene mutation requiring low volume blood samples. Environ. Mol. Mutagen. 56 (2015), 366–377.
11. [11] Horibata, K., Ukai, A., Kimoto, T., Suzuki, T., Kamoshita, N., Masumura, K., Nohmi, T., Honma, M., Evaluation of in vivo genotoxicity induced by N-ethyl-N-nitrosourea, benzo[a]pyrene, and 4-nitroquinoline-1-oxide in the Pig-a and gpt assays. Environ. Mol. Mutagen. 54 (2013), 747–754.
12. [12] Kimoto, T., Horibata, K., Chikura, S., Hashimoto, K., Itoh, S., Sanada, H., Muto, S., Uno, Y., Yamada, M., Honma, M., Interlaboratory trial of the rat Pig-a mutation assay using an erythroid marker HIS49 antibody. Mutat. Res. 755 (2013), 126–134.
13. [13] Araten, D.J., Luzzatto, L., The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108 (2006), 734–736.
14. [14] Dertinger, S.D., Phonethepswath, S., Weller, P., Nicolette, J., Murray, J., Sonders, P., Vohr, H.-W., Shi, J., Krsmanovic, L., Gleason, C., Custer, L., Henwood, A., Sweder, K., Stankowski, L.F., Roberts, D.J., Giddings, A., Kenny, J., Lynch, A.M., Defrain, C., Nesslany, F., van der Leede, B.-j.M., Van Doninck, T., Schuermans, A., Tanaka, K., Hiwata, Y., Tajima, O., Wilde, E., Elhajouji, A., Gunther, W.C., Thiffeault, C.J., Shutsky, T.J., Fiedler, R.D., Kimoto, T., Bhalli, J.A., Heflich, R.H., MacGregor, J.T., International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories. Environ. Mol. Mutagen. 52 (2011), 690–698.
15. [15] Araten, D.J., Krejci, O., Ditata, K., Wunderlich, M., Sanders, K.J., Zamechek, L., Mulloy, J.C., The rate of spontaneous mutations in human myeloid cells. Mutat. Res. 749 (2013), 49–57.
16. [16] Horibata, K., Ukai, A., Honma, M., Evaluation of rats’ in vivo genotoxicity induced by N-ethyl-N-nitrosourea in the RBC Pig-a, PIGRET, and gpt assays. Genes Environ. 36 (2014), 199–202.
17. [17] Kimoto, T., Chikura, S., Suzuki, K., Kobayashi, X.m., Itano, Y., Horibata, K., Honma, M., Dobrovolsky, V.N., Heflich, R.H., Miura, D., Kasahara, Y., Further development of the rat Pig-a mutation assay: measuring rat Pig-a mutant bone marrow erythroids and a high throughput assay for mutant peripheral blood reticulocytes. Environ. Mol. Mutagen. 52 (2011), 774–783.
18. [18] Miura, D., Shaddock, J.G., Mittelstaedt, R.A., Dobrovolsky, V.N., Kimoto, T., Kasahara, Y., Heflich, R.H., Analysis of mutations in the Pig-a gene of spleen T-cells from N-ethyl-N-nitrosourea-treated Fisher 344 rats. Environ. Mol. Mutagen. 52 (2011), 419–423.
19. [19] Revollo, J., Pearce, M.G., Petibone, D.M., Mittelstaedt, R.A., Dobrovolsky, V.N., Confirmation of Pig-a mutation in flow cytometry-identified CD48-deficient T-lymphocytes from F344 rats. Mutagenesis 30 (2015), 315–324.
20. [20] Ware, R.E., Rosse, W.F., Hall, S.E., Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood 86 (1995), 1586–1589.
21. [21] Erlichman, C., Novel chemotherapeutic agents in clinical development. Curr. Opin. Oncol. 3 (1991), 1037–1042.
22. [22] Ross, D.D., Cuddy, D.P., Molecular effects of 2’,2’-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem. Pharmacol. 48 (1994), 1619–1630.
23. [23] Mosconi, A.M., Crino, L., Tonato, M., Combination therapy with gemcitabine in non-small cell lung cancer. Eur. J. Cancer 33:Suppl. (1) (1997), S14–17.
24. [24] Aydemir, N., Bilaloglu, R., Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat. Res. 537 (2003), 43–51.
25. [25] Aydemir, N., Celikler, S., Bilaloglu, R., In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes. Mutat. Res. 582 (2005), 35–41.
26. [26] Shirasaka, T., Shimamoto, Y., Fukushima, M., Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53 (1993), 4004–4009.
27. [27] Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., Fukushima, M., Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996), 548–557.
28. [28] Kurakawa, E., Kasuga, I., Ishizuka, S., Yoshida, T., Kunisawa, A., Minemura, K., Utsumi, K., Ohyashiki, K., Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Jpn. J. Clin. Oncol. 31 (2001), 284–286.
29. [29] Wilson, P.M., Danenberg, P.V., Johnston, P.G., Lenz, H.J., Ladner, R.D., Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat. Rev. Clin. Oncol. 11 (2014), 282–298.
30. [30] Yajima, N., Kondo, K., Morita, K., Reverse mutation tests in Salmonella typhimurium and chromosomal aberration tests in mammalian cells in culture on fluorinated pyrimidine derivatives. Mutat. Res. 88 (1981), 241–254.
31. [31] Ohuchida, A., Kouchi, Y., Sato, S., Maeda, Y., [Mutagenicity study of a new antineoplastic agent S-1, and its components CDHP, and Oxo]. J. Toxicol. Sci. 21:Suppl. (3) (1996), 675–689.
32. [32] Japanese Environmental Mutagen Society-Mammalian Mutagenicity Study Group, H., Suzuki, H., Takasawa, H., Kobayashi, K., Terashima, Y., Shimada, Y., Ogawa, I., Tanaka, J., Imamura, T., Miyazaki, A., Hayashi, M., Evaluation of a liver micronucleus assay with 12 chemicals using young rats (II): a study by the Collaborative Study Group for the Micronucleus Test/Japanese Environmental Mutagen Society-Mammalian Mutagenicity Study Group. Mutagenesis 24 (2009), 9–16.
33. [33] Zhou, C., Zhang, M., Huang, P., Tu, H., Wang, Z., Dertinger, S.D., Torous, D.K., Chang, Y., Assessment of 5-fluorouracil and 4-nitroquinoline-1-oxide in vivo genotoxicity with Pig-a mutation and micronucleus endpoints. Environ. Mol. Mutagen. 55 (2014), 735–740.